The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …

Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance,
because it is associated with a poor quality of life and increased mortality. While impaired …

Abstract Aim Cardiotoxicity (CTox) is a major side effect of cancer therapies, but uniform
diagnostic criteria to guide clinical and research practices are lacking. Methods and results …

The co‐occurrence of cancer and heart failure (HF) represents a significant clinical
drawback as each disease interferes with the treatment of the other. In addition to shared …

Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Emerging evidence supports that cancer incidence is increased in patients with
cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from …